IN8bio, Inc. INAB
1.20
0.01
0.84%
as of 25 Sep
- Market cap
- $11.1M
- P/E
- 0.0×
Follow INAB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
6.91 | 8.82 | 10.50 | 8.21 |
Net Debt/EBITDA |
3.09 | 6.00 | 4.60 | 4.01 | |
Debt/Assets |
0.38% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.91 | 0.43 | 0.97 | 0.78 | |
Capex/Depreciation |
0.00 | 0.00 | (0.02) | (0.51) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.78) | (0.49) | (0.25) | (0.20) | |
Cash per Share |
2.36 | 6.19 | 1.13 | 0.92 | |
Shareholders Equity per Share |
2.91 | 6.30 | 1.17 | 0.94 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.91 | 6.30 | 1.17 | 0.94 | |
Free Cash Flow |
(3.52) | (2.14) | (4.96) | (3.98) | |
Working Capital |
10.07 | 24.72 | 20.50 | 16.24 | |
Capital Expenditures |
— | — | (0.01) | (0.23) | |
Net Current Asset Value |
8.19 | 23.16 | 19.18 | 15.11 | |
| Other line items | |||||
Quick Ratio |
6.28 | 8.57 | 10.17 | 7.97 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.78) | (0.49) | (0.25) | (0.19) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Average Payables |
0.67 | 0.35 | 0.51 | 0.41 | |
Average Assets |
16.37 | 26.61 | 23.07 | 20.56 | |
Average Common Equity |
10.89 | 21.02 | 18.33 | 16.80 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates